Development of a reminiscence therapy online platform with machine learning to increase engagement with people living with dementia and their care partners

开发具有机器学习功能的回忆疗法在线平台，以增加与痴呆症患者及其护理伙伴的互动

• 批准号: 10079369
• 负责人: Lisbeth Sanders
• 金额: $ 138.42万
• 依托单位: LIFEBIO INC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10079369
• 关键词: Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Artificial Intelligence; Assisted Living Facilities; Behavioral Symptoms; Books; Caregivers; Caring; Cause of Death; Cessation of life; Cognition; Communication; Consumption; Data; Dementia; Dependence; Development; Disease; Elderly; Elements; Empathy; Environment; Evaluation; Event; Exercise Therapy; Family Caregiver; Family member; Feedback; Financial Hardship; Focus Groups; Generations; Health Personnel; Impaired cognition; Individual; Institutes; Internet; Intervention; Interview; Knowledge; Life; Machine Learning; Memory; Mental Health; Modification; Monitor; Moods; Music; Nature; Nursing Homes; Oral; Outcome; Output; Participant; Patients; Persons; Phase; Pilot Projects; Procedures; Process; Qualitative Evaluations; Quality of life; Quantitative Evaluations; Reporting; Research; Residential Treatment; Side; Small Business Innovation Research Grant; Source; Speech; Surveys; Symptoms; System; Techniques; Testing; Text; Time; Training; United States Centers for Medicare and Medicaid Services; Work; aged; base; caregiving; dementia care; depressive symptoms; design; effective intervention; experience; improved; interactive tool; life history; long term memory; novel; person centered; physical conditioning; point of care; programs; prototype; psychological symptom; symptomatology; tool; usability; user-friendly; web site

PROJECT SUMMARY Almost 6 million Americans are living with Alzheimer’s disease (AD) or AD-related dementias, and the number of affected individuals is rapidly growing. Symptoms include impaired cognition, resulting in difficulty in performing daily activities and consequent functional dependence on others. The progressive nature of AD and ADRD can result in increasing degrees of care required from professional and family caregivers. Non- pharmacologic interventions positively influence cognition, mood, and other behavioral and psychological symptoms of dementia, and one well-established intervention, life story work (the use of written and oral life histories), serves as an effective technique that can elicit conversation and memories in those with AD and ADRD. However, generating useful life story materials is a time-consuming task for caregivers. To overcome this barrier, LifeBio Inc. is developing a reminiscence therapy platform —LifeBio MemoryTM— with a novel machine-learning-based application that converts speech to text and generates life stories to serve as an interactive tool to cultivate communication between people living with dementia and their family and caregivers. The LifeBio MemoryTM platform application will elicit and store individuals’ stories, photos, and videos and ultimately deliver personalized, point-of-care reminiscence therapy exercises for patients. In preliminary work supporting this Direct-to-Phase II proposal, LifeBio Inc. partnered with the Benjamin Rose Institute on Aging to conduct a pilot study in nursing homes, which showed a significant decrease in depressive symptoms among participants in LifeBio Inc.’s intervention and revealed that the majority of participants considered knowledge of their life story to be important for caregivers, while caregivers also reported positive experiences in relation to the impact of the intervention on caregiving. In this project we will: 1) Develop prototype enhancements of the existing LifeBio program and conduct focus group evaluations of these prototypes with 12 existing or former LifeBio users, 20 dementia care professionals familiar with LifeBio and 6 older adults with early-stage dementia to help maintain person-centered practices throughout the research process; 2) Finalize the LifeBio Memory product, which will include the development of a system to automatically record and process individuals’ life stories. 3) Conduct a full-scale fidelity trial of the complete package with 40 care professionals and 160 dementia care dyads across within an assisted living setting. The product of this Direct-to-Phase II proposal, LifeBio Memory™, will be a novel, scalable, and easily implemented solution through which caregivers and healthcare providers can offer person-centered care to people living with AD and AD-related dementias.

项目摘要 近600万美国人患有阿尔茨海默氏病（AD）或与广告相关的痴呆症，数量 受影响的个体正在迅速增长。症状包括认知受损，导致困难 进行日常活动，然后对他人进行功能依赖。广告的进步性质和 ADRD可能会导致专业和家庭护理人员所需的越来越多的护理。非- 药理学干预措施积极影响认知，情绪以及其他行为和心理 痴呆症的症状以及一种公认的干预措施，生活故事工作（使用书面和口腔生活 Hertories），是一种有效的技术，可以在患有广告的人中引起对话和回忆 adrd。但是，生成有用的生活故事材料是护理人员的一项耗时的任务。克服 这个障碍，Lifebio Inc.正在开发一个回忆疗法平台-Lifebio MemoryTM，并带有小说 基于机器学习的应用程序将语音转换为文本并生成生活故事，以作为一个 互动工具，以培养痴呆症患者与家人和照料者之间的沟通。 LifeBio MemoryTM平台应用程序将引起并存储个人的故事，照片和视频，并且 最终为患者提供了个性化的护理提醒疗法。在初步工作中 Lifebio Inc.支持这一直接阶段II提案，与本杰明·罗斯（Benjamin Rose）老龄化研究所合作 在护士之家进行试点研究，该研究显示 Lifebio Inc.的干预参与者，并透露，大多数参与者都考虑 他们的生活故事对看护人很重要，而照顾者也报告了与 干预对护理的影响。在这个项目中，我们将：1）开发原型增强 现有的lifebio计划并通过12个现有或形式对这些原型进行焦点小组评估 Lifebio用户，熟悉Lifebio的20名痴呆症护理专业人员和6名患有早期痴呆症的老年人 在整个研究过程中帮助维持以人为本的实践； 2）最终确定lifebio记忆 产品将包括开发系统以自动记录和处理个人生活的系统 故事。 3）对40名护理专业人员和160个痴呆症进行完整套餐的全面忠诚试验 在辅助生活环境中关怀二元组。这个直接到相位II提案的产品，Lifebio Memory™将是一种新颖，可扩展且易于实现的解决方案 提供者可以为拥有广告和广告相关痴呆症的人提供以人为本的护理。